• Michael Olausson, Styrbjörn Friman, Gustaf Herlenius, Christian Cahlin, Ola Nilsson, Svante Jansson, Bo Wängberg, and Håkan Ahlman.
• Sahlgrenska Transplant Institute, Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden.
• Liver Transpl. 2007 Mar 1; 13 (3): 327-33.

AbstractLiver transplantation can be a therapeutic option for individual patients with neuroendocrine tumors metastatic only to the liver. In this consecutive series of 15 patients (5 multivisceral and 10 orthotopic liver transplantations) with well-differentiated carcinoids, or endocrine pancreatic tumors, we allowed higher proliferation rate (Ki67 <10%), large tumor burden, and higher age than previous studies. Liver transplantation offered good relief of symptoms, long disease-free intervals, and potential cure in individual patients. The survival of grafts and patients compared well with transplantation for benign disease. The overall 5-year survival was 90%. The recurrence-free survival of both multivisceral and liver transplantation related to the time after transplantation (about 20% at 5 years) despite inclusion of patients with higher risk. In conclusion, the critical prognosticators for long-term outcome still remain to be defined. The experience with multivisceral transplantation for patients with endocrine tumors of the pancreatic head is still limited.(c) 2007 AASLD.

29 keywords...

hide…